C4A and schizophrenia: In future clinical studies, investigation of the therapeutic effects of the inhibition of microglial activation in more suitable cohorts of patients with schizophrenia or individuals with first-degree relatives with schizophrenia and a high risk of microglial activation, such as those with the complement component C4 variant, would be of interest.